Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBITDA Margin (2016 - 2025)

Sanara MedTech's EBITDA Margin history spans 15 years, with the latest figure at 17.03% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 162.0% year-over-year to 17.03%; the TTM value through Dec 2025 reached 12.53%, up 385.0%, while the annual FY2025 figure was 16.5%, 594.0% up from the prior year.
  • EBITDA Margin reached 17.03% in Q4 2025 per SMTI's latest filing, down from 18.64% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 43.41% in Q4 2022 to a low of 34.36% in Q1 2022.
  • Average EBITDA Margin over 5 years is 0.33%, with a median of 2.11% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: surged 5146bps in 2021, then plummeted -4088bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 34.03% in 2021, then rose by 28bps to 43.41% in 2022, then tumbled by -94bps to 2.54% in 2023, then skyrocketed by 507bps to 15.41% in 2024, then grew by 11bps to 17.03% in 2025.
  • Per Business Quant, the three most recent readings for SMTI's EBITDA Margin are 17.03% (Q4 2025), 18.64% (Q3 2025), and 10.32% (Q2 2025).